Cross-sectional and longitudinal immunoprofiling of Mount Sinai’s COVID-19 patients:
As one of the largest hospitals in New York City, the epicenter of the American COVID-19 outbreak, Mount Sinai has seen and treated a disproportionate number of COVID-19 patients.
To study these patients, we have developed one of the most extensive COVID-19 biobanks, cataloguing longitudinally-collected blood samples from hundreds of patients with varying disease severity over the course of their hospital stay. These samples will be studied by CyTOF profiling of PBMCs, as well as multiplex o-link seromics, allowing us to measure hundreds of immune parameters at each time point. These molecular features will be analyzed together with the matched clinical data for these patients.
This project is in collaboration with the Human Immune Monitoring center, as well as other groups at Mount Sinai who are collecting additional data including bulk transcriptomics and whole exome sequencing, in order to understand how viral infection may interact with host features at the genomic level to engage an inflammatory response. This platform has also been employed to follow patients enrolled on multiple clinical trials, in order to understand how therapies act to modulate the inflammatory state, and to identify biomarkers predictive of disease course and treatment response.